These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 34672807)

  • 1. Re: "Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2" by Krsak
    Mishra BK; Bhattacharya D; Kshatri JS; Pati S
    Viral Immunol; 2021 Nov; 34(9):658. PubMed ID: 34672807
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: "Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2" by Krsak
    Mungmunpuntipantip R; Wiwanitkit V
    Viral Immunol; 2021 Oct; 34(8):582. PubMed ID: 34491120
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to Mishra
    Krsak M; Harry BL; Palmer BE; Franco-Paredes C
    Viral Immunol; 2021 Nov; 34(9):659-660. PubMed ID: 34672802
    [No Abstract]   [Full Text] [Related]  

  • 4. Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination.
    Lippi G; Sciacovelli L; Trenti T; Plebani M;
    Clin Chem Lab Med; 2021 Jul; 59(8):1333-1335. PubMed ID: 33578505
    [No Abstract]   [Full Text] [Related]  

  • 5. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2.
    Mveang Nzoghe A; Essone PN; Leboueny M; Maloupazoa Siawaya AC; Bongho EC; Mvoundza Ndjindji O; Avome Houechenou RM; Agnandji ST; Djoba Siawaya JF
    Immun Inflamm Dis; 2021 Mar; 9(1):128-133. PubMed ID: 33320447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series.
    Connolly CM; Teles M; Frey S; Boyarsky BJ; Alejo JL; Werbel WA; Albayda J; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
    Ann Rheum Dis; 2022 Feb; 81(2):291-293. PubMed ID: 34493492
    [No Abstract]   [Full Text] [Related]  

  • 8. B careful: Humoral responses and COVID-19 severity.
    Fanous H; Guerrero-Pena A; Pillai A
    Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33277373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
    Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
    Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
    [No Abstract]   [Full Text] [Related]  

  • 10. The fragility of humoral immunity as a physiological safety marker for healthcare workers to return after COVID-19 convalescence.
    Silva VL; Dias VC; Watanabe ASA; Ferreira Machado AB; Furtado AO; Diniz CG
    J Microbiol Immunol Infect; 2021 Feb; 54(1):141-143. PubMed ID: 32868192
    [No Abstract]   [Full Text] [Related]  

  • 11. Absence of SARS-CoV-2 antibodies in health care workers of a tertiary referral hospital for COVID-19 in southern Vietnam.
    Chau NVV; Toan LM; Man DNH; Thao HP; Lan NPH; Ty DTB; Hieu DK; Tien NTM; Ngoc NM; Hung LM; Dung NT; Thanh TT; Truong NT; Thwaites G; Tan LV
    J Infect; 2021 Jan; 82(1):e36-e37. PubMed ID: 33221367
    [No Abstract]   [Full Text] [Related]  

  • 12. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients.
    Deng Y; Li Y; Yang R; Tan W
    Cell Mol Immunol; 2021 Aug; 18(8):2040-2041. PubMed ID: 34267334
    [No Abstract]   [Full Text] [Related]  

  • 13. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays.
    Cuykx M; Mortelé O; Jansens H; Schouwers S; Meskal A; Hoffbauer I; Peeters B
    Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115486. PubMed ID: 34332306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
    Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
    Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and immunological characteristics in COVID-19 convalescent patients.
    Su Z; Hu W; Liu Q; Zhang Y; Chen T; Zhou Y; Zhang Z; Chen Y; Yang R; Xiong Y; Wang X
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2669-2676. PubMed ID: 34625887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2.
    Majdoubi A; Michalski C; O'Connell SE; Dada S; Narpala S; Gelinas J; Mehta D; Cheung C; Winkler DF; Basappa M; Liu AC; Görges M; Barakauskas VE; Irvine M; Mehalko J; Esposito D; Sekirov I; Jassem AN; Goldfarb DM; Pelech S; Douek DC; McDermott AB; Lavoie PM
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33720905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19.
    Mazzoni A; Di Lauria N; Maggi L; Salvati L; Vanni A; Capone M; Lamacchia G; Mantengoli E; Spinicci M; Zammarchi L; Kiros ST; Rocca A; Lagi F; Colao MG; Parronchi P; Scaletti C; Turco L; Liotta F; Rossolini GM; Cosmi L; Bartoloni A; Annunziato F;
    J Clin Invest; 2021 Jun; 131(12):. PubMed ID: 33939647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors.
    Frieman M; Harris AD; Herati RS; Krammer F; Mantovani A; Rescigno M; Sajadi MM; Simon V
    EBioMedicine; 2021 Jun; 68():103401. PubMed ID: 34051441
    [No Abstract]   [Full Text] [Related]  

  • 20. Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity.
    Wu J; Liang BY; Fang YH; Wang H; Yang XL; Shen S; Chen LK; Li SM; Lu SH; Xiang TD; Liu J; Le-Trilling VTK; Lu MJ; Yang DL; Deng F; Dittmer U; Trilling M; Zheng X
    Front Immunol; 2021; 12():722027. PubMed ID: 34489971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.